While our understanding of functional rearrangements in breast cancer is emerging, other overarching challenges remain. These challenges include how to ensure the quality and depth of sequencing reads, standardized reporting and validation across studies, tumor sample purity, clonal heterogeneity, and multifocality. Less well-understood transposable elements such as LINE1 and Alu, which have not been addressed in this review, are also being investigated to define their role in genomic instability and cancer.128,129 Newer techniques of genome editing such as CRISPR, which allow precise manipulation of the genome at a desired location, are under study to model genomic alterations more efficiently and also to develop gene therapy.130–132 Nevertheless, as our understanding grows with affordable, but sophisticated, sequencing strategies and metagenomic approaches, rearrangement-based biomarkers will be pivotal for the practice of precision medicine in breast cancer.
Bhavna S. Paratala,1,2 Sonia C. Dolfi,1 Hossein Khiabanian,3 Lorna Rodriguez-Rodriguez,4 Shridar Ganesan,1 and Kim M. Hirshfield1
1Department of Medicine, Division of Medical Oncology, Rutgers Cancer Institute of New Jersey, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA.
2Department of Cellular and Molecular Pharmacology, Rutgers Robert Wood Johnson Medical School, Piscataway, NJ, USA.
3Department of Pathology, Division of Medical Informatics, Rutgers Cancer Institute of New Jersey, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA.
4Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Rutgers Cancer Institute of New Jersey, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA.
Correspondence: E-mail: [email protected]
We would like to acknowledge Ms. Jacqueline Harris for her support and assistance.
ACADEMIC EDITOR: Barbara Guinn, Editor in Chief
PEER REVIEW: Seven peer reviewers contributed to the peer review report. Reviewers’ reports totaled 1324 words, excluding any confidential comments to the academic editor.
FUNDING: This research was supported by a generous gift to the Genetics Diagnostics to Cancer Treatment Program of the Rutgers Cancer Institute of New Jersey and RUCDR Infinite Biologics, The Val Skinner Foundation, NIH/NCI P30CA072720, AHEPA Foundation, and The Ruth Estrin Goldberg Memorial for Cancer Research. The authors confirm that the funder had no influence over the study design, content of the article, or selection of this journal.
COMPETING INTERESTS: Authors disclose no potential conflicts of interest.
Paper subject to independent expert blind peer review. All editorial decisions made by independent academic editor. Upon submission manuscript was subject to anti-plagiarism scanning. Prior to publication all authors have given signed confirmation of agreement to article publication and compliance with all applicable ethical and legal requirements, including the accuracy of author and contributor information, disclosure of competing interests and funding sources, compliance with ethical requirements relating to human and animal study participants, and compliance with any copyright requirements of third parties. This journal is a member of the Committee on Publication Ethics (COPE).
Wrote the first draft of the manuscript: BSP and KMH. Contributed to the writing of the manuscript: BSP, SCD, HK, SG, and KMH. Jointly developed the structure and arguments for the paper: BSP and KMH. Made critical revisions and approved final version: BSP, SCD, HK, LRR, SG, and KMH. All authors reviewed and approved of the final manuscript.
1. Drier Y, Lawrence MS, Carter SL, et al. Somatic rearrangements across cancer reveal classes of samples with distinct patterns of DNA breakage and rearrangement-induced hypermutability. Genome Res. 2013;23(2):228–235. [PMC free article] [PubMed]
2. Mitelman F, Johansson B, Mertens F. Fusion genes and rearranged genes as a linear function of chromosome aberrations in cancer. Nat Genet. 2004;36(4):331–334. [PubMed]
4. Rowley JD. A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and giemsa staining. Nature. 1973;243(5405):290–293. [PubMed]
5. Groffen J, Stephenson JR, Heisterkamp N, de Klein A, Bartram CR, Grosveld G. Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell.1984;36(1):93–99. [PubMed]
6. Dalla-Favera R, Bregni M, Erikson J, Patterson D, Gallo RC, Croce CM. Human c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. Proc Natl Acad Sci U S A. 1982;79(24):7824–7827. [PMC free article] [PubMed]
7. Janknecht R. EWS-ETS oncoproteins: the linchpins of Ewing tumors. Gene. 2005;363:1–14. [PubMed]
8. Delattre O, Zucman J, Plougastel B, et al. Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature. 1992;359(6391):162–165. [PubMed]
9. Dal Cin P, Rao U, Jani-Sait S, Karakousis C, Sandberg AA. Chromosomes in the diagnosis of soft tissue tumors. I. Synovial sarcoma. Mod Pathol. 1992;5(4):357–362. [PubMed]
10. Cheung Lydia WT, Yu S, Zhang D, et al. Naturally occurring neomorphic PIK3R1 mutations activate the MAPK pathway, dictating therapeutic response to MAPK pathway inhibitors. Cancer Cell. 2014;26(4):479–494. [PMC free article] [PubMed]
12. Kohsaka S, Shukla N, Ameur N, et al. A recurrent neomorphic mutation in MYOD1 defines a clinically aggressive subset of embryonal rhabdomyosarcoma associated with PI3K-AKT pathway mutations. Nat Genet. 2014;46(6):595–600. [PMC free article] [PubMed]
13. Ward PS, Patel J, Wise DR, et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzymatic activity that converts α-ketoglutarate to 2-hydroxyglutarate. Cancer Cell. 2010;17(3):225–234. [PMC free article] [PubMed]
14. Schnitt SJ. Classification and prognosis of invasive breast cancer: from morphology to molecular taxonomy. Mod Pathol. 2010;23(S2):S60–S64. [PubMed]
15. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747–752. [PubMed]
16. Harvey JM, Clark GM, Osborne CK, Allred DC. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol. 1999;17(5):1474–1481. [PubMed]
17. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2002;20(3):719–726.[PubMed]
18. Balko JM, Giltnane JM, Wang K, et al. Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets. Cancer Discov. 2014;4(2):232–245. [PMC free article] [PubMed]
19. André F, Bachelot T, Campone M, Arnedos Ballester M, Commol F, Gonçalves A. Array CGH and DNA sequencing to personalize therapy for metastatic breast cancer: a prospective national trial (UNICANCER SAFIR-01) Ann Oncol. 2012;23(suppl):9.
20. Pierga J, Asselain B, Alsafadi S. A prospective randomized trial evaluating gene expression arrays to select neoadjuvant chemotherapy regimen for operable breast cancer: first report of the REMAGUS04 trial; Paper presented at: 2012 ESMO Congress; 2012. Abstract 2012.